Newly Published Systematic Review Confirms Strength of Evidence & Outlines Appropriate Use Criteria for Integration of Decisi...
October 07 2019 - 7:00AM
Business Wire
Study published recently in SKIN: The Journal
of Cutaneous Medicine
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer
diagnostics company providing personalized genomic information to
improve cancer treatment decisions, today announced the publication
of an expert panel consensus statement that includes appropriate
use criteria for DecisionDx®-Melanoma in patients with cutaneous
melanoma. The study was published in the peer-reviewed journal
SKIN: The Journal of Cutaneous Medicine.
A panel of nine expert dermatologists, dermatologic surgeons,
and dermatopathologists performed a systematic review of published
evidence and developed appropriate use criteria supporting the
integration of DecisionDx-Melanoma and two other validated, widely
used molecular tests in melanoma patient care. The systematic
review of peer-reviewed medical literature identified studies
relating to clinical validity, outcomes or utility of
DecisionDx-Melanoma. Employing a modified Delphi consensus
technique, the panel determined the level of evidence for
publications as well as an overall strength of recommendation for
selected indications using standard Strength of Recommendation
Taxonomy (SORT) methodology.
Key Findings
- Eleven publications were identified as achieving quality levels
1 or 2, with two publications achieving the highest level of
evidence (Level 1).
- Eight consensus-based appropriate use criteria recommendations
achieved a rating of “A” or “B”, with “A” rating indicating the
highest strength of recommendation.
- The expert consensus-based appropriate use criteria provide an
evidence-based framework to integrate the DecisionDx-Melanoma test
into the management of patients with cutaneous melanoma.
“This important publication is the first to provide expert
consensus-based appropriate use criteria to help clinicians
integrate technologies like the DecisionDx-Melanoma test into their
melanoma practice,” said study co-author Darrell S. Rigel, M.D.,
M.S., Clinical Professor at New York University (NYU) School of
Medicine. “The DecisionDx-Melanoma test has been well validated as
a predictor of risk of metastasis or recurrence. The appropriate
use criteria recommendations align with the current clinical use of
DecisionDx-Melanoma to guide the post-diagnostic decisions to
perform a sentinel lymph node biopsy surgical procedure in certain
patients, and determine appropriate management plans regarding
follow-up regimens, inclusion of imaging and referral to
oncology.”
The full published study can be accessed at the journal’s
website.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage
dermatologic cancer company focused on providing physicians and
their patients with personalized, clinically actionable genomic
information to make more accurate treatment decisions. The Company
currently offers tests for patients with cutaneous melanoma
(DecisionDx®-Melanoma, DecisionDx®-CMSeq; www.SkinMelanoma.com) and uveal melanoma
(DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq;
www.MyUvealMelanoma.com), with
products in development for other underserved cancers, the two most
advanced of which are focused on patients with cutaneous squamous
cell carcinoma, and patients who have a difficult-to-diagnose
pigmented lesion. Castle Biosciences is based in Friendswood, Texas
(Houston), and has laboratory operations in Phoenix, Arizona. For
more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-UM,
DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle
Biosciences, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191007005049/en/
Derek Maetzold, President and CEO 866-788-9007
IR@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Castle Biosciences (NASDAQ:CSTL)
Historical Stock Chart
From Sep 2023 to Sep 2024